# NSABP Foundation

Source: https://onco.cc/companies/nsabp-foundation/  
OnCo record `nsabp-foundation` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The legacy US surgical adjuvant trials group that proved lumpectomy equals mastectomy, tamoxifen prevents breast cancer and trastuzumab cures more HER2-positive disease.

## Summary

Founded in 1958 and led for decades by Bernard Fisher, the NSABP ran the trials that rewrote breast cancer surgery and adjuvant therapy: B-04 and B-06 showed breast conservation equals mastectomy, B-14 and B-20 provided the samples that validated the Oncotype DX recurrence score, P-1 showed tamoxifen prevents breast cancer, B-31 (with NCCTG N9831) established adjuvant trastuzumab, and B-32 validated sentinel node biopsy. It also ran colorectal adjuvant trials (C-series). NSABP merged with RTOG and GOG into NRG Oncology in 2014; the NSABP Foundation continues industry-partnered trials such as KATHERINE (with the German Breast Group) and the neoadjuvant B-series.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: National Surgical Adjuvant Breast and Bowel Project; NSABP
- Tags: cooperative-group
- HQ: Pittsburgh, PA
- Type: cooperative-group
- Website: https://www.nsabp.org

## Notes

- B-04 / B-06 (breast conservation)
- P-1 (tamoxifen prevention)
- B-31 (adjuvant trastuzumab)
- KATHERINE (with GBG)
- Oncotype DX validation (B-14, B-20)

## Sources

- NSABP Foundation: https://www.nsabp.org

## Connected records

- drugs: [Oncotype DX](https://onco.cc/drugs/oncotype-dx/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/), [Surgery & Interventional](https://onco.cc/fronts/surgery/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/)
- companies: [German Breast Group (GBG)](https://onco.cc/companies/gbg/), [NRG Oncology](https://onco.cc/companies/nrg-oncology/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- trials: [HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)](https://onco.cc/trials/hera-b31-n9831/), [KATHERINE](https://onco.cc/trials/katherine/)
- people: [Norman Wolmark](https://onco.cc/people/norman-wolmark/), [Priya Rastogi](https://onco.cc/people/priya-rastogi/)

---
JSON: https://onco.cc/api/v1/entities/nsabp-foundation.json